### Early Warning System

# EIB-20220855 ROMANIAN PHARMACEUTICAL R&D PROJECT



### **Quick Facts**

Countries	Romania
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2023-09-26
Borrower	ANTIBIOTICE SA
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 26.42 million
Loan Amount (USD)	\$ 26.42 million
Project Cost (USD)	\$ 100.41 million

### **Project Description**

As stated on the project disclosure page, the promoter is a Romanian mid-cap in the pharmaceutical sector. The project will support research and development activities to develop new pharmaceutical products addressing unmet medical needs and investments to to implement the company's digitalisation processes.

The aim is to accelerate the promoter's growth and development plans by upscaling the manufacturing capacities and capabilities of essential (generic) drugs.



### **Investment Description**

• European Investment Bank (EIB)

### **Private Actors Description**

Antibiotice SA is a pharmaceutical company with headquarters in Romania. The company was founded in 1955 and, as stated on the company's website, it "is one of the most important Romanian producers of generic drugs".





Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Antibiotice SA	Client	Industry and Trade



#### **Contact Information**

#### Client - Antibiotice SA:

Address: 1 Valea Lupului Street, Iasi 707410, Romania

Phone: +40 232 209 000 / +40 232 220 040 / +40 372 065 000 / +40 372

065 633

Email: office@antibiotice.ro

Website: https://www.antibiotice.ro/en/

#### **ACCESS TO INFORMATION**

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

#### **ACCOUNTABILITY MECHANISM OF EIB**

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints mechanism policy en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces



#### **Bank Documents**

• Environmental and Social Data Sheet (ESDS) - ROMANIAN PHARMACEUTICAL R&D PROJECT [Original Source]

#### Media

• Antibiotice announces the selection of the European Investment Bank to finance investment projects w